Metabolite profiling of remibrutinib in rat and human liver microsomes using liquid chromatography combined with benchtop orbitrap high‐resolution mass spectrometry
Biomedical Chromatography · 2023-12 · 37 (12)
DOI: 10.1002/bmc.5737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 31.08.2023. Verfasst von Xinxin Lai und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University of Industrial Technology, Zhengzhou, China. Hauptthemen laut MEDLINE: Microsomes, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Remibrutinib is a potent and highly selective covalent Bruton's tyrosine kinase inhibitor that is undergoing clinical development for the treatment of autoimmune diseases. The present study was undertaken to investigate the in vitro metabolism of remibrutinib and to propose its biotransformation pathways. The metabolites were generated by incubating remibrutinib (2 μ m ) with human and rat liver microsomes at 37°C for 30 min. Ultra‐high‐performance liquid chromatography combined with benchtop orbitrap high‐resolution mass spectrometry was used to identify and characterize the metabolites of remibrutinib. Compound Discoverer software was employed to process the acquired data. In rat liver microsomes, a total of 18 metabolites have been identified and characterized among which three (M8, M12 and M13) were identified as the most abundant metabolites. In human liver microsomes, a total of 16 metabolites have been identified, and M8 and M12 were identified as the predominant metabolites. All the metabolites were nicotinamide adenine dinucleotide phosphate dependent. The major metabolic changes were found to be oxygenation, dealkylation, demethylation, epoxidation and hydrolysis. The present study comprehensively reports the in vitro metabolism of remibrutinib mentioning 20 metabolites. These findings will help investigation of remibrutinib disposition and safety evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University of Industrial Technology, Zhengzhou, China.
ORCID-Profile: Lingpan Lu
Zitieren
APA
Lai, X., Liu, J., Li, W., Qiao, M., Qiu, M., & Lu, L. (2023). Metabolite profiling of remibrutinib in rat and human liver microsomes using liquid chromatography combined with benchtop orbitrap high‐resolution mass spectrometry. Biomedical Chromatography, 37(12). https://doi.org/10.1002/bmc.5737
Vancouver
Lai X, Liu J, Li W, Qiao M, Qiu M, Lu L. Metabolite profiling of remibrutinib in rat and human liver microsomes using liquid chromatography combined with benchtop orbitrap high‐resolution mass spectrometry. Biomedical Chromatography. 2023;37(12). doi:10.1002/bmc.5737
BibTeX
@article{Lai2023,
author = {Lai, Xinxin and Liu, Jinhai and Li, Wenyuan and Qiao, Min and Qiu, Mingheng and Lu, Lingpan},
title = {Metabolite profiling of remibrutinib in rat and human liver microsomes using liquid chromatography combined with benchtop orbitrap high‐resolution mass spectrometry},
journal = {Biomedical Chromatography},
year = {2023},
volume = {37},
number = {12},
doi = {10.1002/bmc.5737}
}
EUVIMED